Addimmune™ Launch Party Highlights

Addimmune™ launched in June 2023 with the sole purpose of curing HIV. Building upon the success of the American Gene Technologies® HIV clinical trial, Addimmune is singularly focused on developing and commercializing an effective and lasting cure for HIV using gene and cell therapy.

CEO Jeff Galvin announced encouraging results from the Phase 1 clinical trial which spurred the creation of Addimmune. To celebrate, several hundred leaders and stakeholders from Montgomery County and beyond joined our team in commemorating this major milestone.

Visit our website: https://www.addimmune.com/
Subscribe to our newsletter: https://www.addimmune.com/in-the-news/

Follow Addimmune on social media:
Facebook:   / addimmune  
Twitter:   / addimmune  
LinkedIn:   / addimmune  
Instagram:   / addimmune  
Threads: https://www.threads.net/@addimmune
Follow Jeff Galvin on social media:
Twitter: @jeffreygalvin   / jeffreygalvin  
LinkedIn:   / jeff-galvin  

Follow AGT on social media:
Facebook:   / amerigene  
Twitter:   / americangene  
LinkedIn:   / american-gene-technologies-international-inc  
Instagram:   / americangenetechnologies  
Threads: https://www.threads.net/@americangene...
Visit AGT’s website: https://www.americangene.com
Subscribe to AGT’s newsletter: https://bit.ly/3ughPNR
Follow Jeff Galvin on social media:
Twitter: @jeffreygalvin   / jeffreygalvin  
LinkedIn:   / jeff-galvin